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ABSTRACT
Prepulse inhibition (PPI) of the acoustic startle response is a preattentive process 
disrupted in schizophrenia. NMDAR-antagonist induced PPI disruption has 
become a prevalent pharmacological model, however knowledge of the 
mechanism underlying NMDAR-antagonist induced PPI deficits (NAlPdef) 
remains incomplete. This work aims to examine the roles of NMDAR subtypes in 
the medial prefrontal cortex (mPFC) and the caudal pontine reticular nucleus 
(PnC) in NAlPdef in rats, and the effects of NMDAR antagonists on PPI and 
startle reactivity over the diurnal cycle. Results indicate that neither the PnC nor 
the diurnal cycle play a role in the mechanism underlying NAlPdef. However, 
microinjections of the NMDAR antagonist MK-801 to the mPFC caused 
significant disruption of PPI, while microinfusion of the NR2B-specific NMDAR 
antagonist ifenprodil to the mPFC caused trend level disruption of PPI. This work 
shows for the first time that NMDARs in the mPFC play a role in the mechanism 
underlying NAlPdef.
Keywords: acoustic startle response, prepulse inhibition, NMDA receptor, 
metabotropic glutamate receptor, schizophrenia, medial prefrontal cortex, caudal 
pontine reticular nucleus, microinfusion, diurnal cycle
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I. INTRODUCTION
Prepulse inhibition (PP1) is the attenuation of the startle response (ASR) caused by a 
strong acoustic stimulus when this stimulus is preceded by a weaker, non-startling 
stimulus (Hoffman & Searle 1965; Hoffman, & Ison 1980; Ison, & Hammond 1971). It is 
widely considered to be an operational measure of sensorimotor gating, one of the 
mechanisms by which an organism filters out irrelevant sensory information (Braff et al 
1978).
The integrity of many of our higher cognitive processes, such as memory, attention, and 
general organization of thought, rely crucially on our ability to preattentively filter out 
irrelevant sensory information. The PPI paradigm has since been used extensively to 
investigate sensorimotor gating deficits in disorders such as Tourette’s syndrome 
(Castellanos et al 1996), bipolar disorder (Giakoumaki et al 2007), post-traumatic stress 
disorder (Grillon et al 1996), obsessive-compulsive disorder (Hoenig et al 2005), panic 
disorder (Ludewig et al 2002), autism (Perry et al 2007), Huntington’s disease (Swerdlow 
et al 1995), nocturnal enuresis (Omitz et al 1999), and most notably schizophrenia 
(Bolino et al 1994; Braff et al 1992; Braff et al 1999; Kumari et al 1999; Kumari et al 
2000; Weike et al 2000).
Initial interest in using PPI to experimentally explore and understand schizophrenia arose 
from clinical evidence that schizophrenic patients exhibit deficiencies in their ability to 
adequately filter out extraneous, disruptive sensory stimuli (Bleuler 1950; Kraepelin 
1919; McGhie, & Chapman 1961; Venables 1964). Symptoms of schizophrenia are 
generally categorized as positive symptoms (delusions, aggression, talkativeness, bizarre 
behaviour, hallucinations, etc.), negative symptoms (affective flattening, poverty of 
speech, loss of motivation, social and emotional withdrawal, poor hygiene, etc.), or 
cognitive symptoms (disorganized thought, memory deficits, inattention, derailment) 
(Geyer 2006; Walker, & Lewine 1988). PPI deficits have been correlated to deficits in 
cognitive function indicators such as measures of distractibility and attention (Karper et
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al 1996) and Rorschach inkblot tests of thought disturbance (Perry et al 1999; Perry, & 
Braff 1994), as well as global functioning levels (Swerdlow et al 2006).
Over the past few decades, the potential role of the N-methyl-D-aspartate receptor 
(NMDAR) system in schizophrenia has emerged as an area of promise in understanding 
the cognitive symptoms of schizophrenia. The administration of non-competitive NMDA 
receptor antagonists induces not only the positive, but also the negative and cognitive 
symptoms of schizophrenia (Javitt 1987; Javitt, & Zukin 1991; Mansbach, & Geyer 1991; 
Krystal et al 1994; Moghaddam 1994). Furthermore, the effects of non-competitive 
NMDA receptor antagonists cannot be reversed by haloperidol, a typical antipsychotic, 
indicating that the mechanisms mediating the cognitive effects of phencyclidine (PCP) 
are independent of the dopaminergic system (Geyer et al 1990; Keith et al 1991). The use 
of NMDAR antagonists has thus become a working model used to investigate the 
cognitive symptoms of schizophrenia. Achieving a greater understanding of the 
mechanism by which NMDAR antagonists exert their effects may provide insight into the 
mechanisms underlying sensorimotor gating deficiencies in humans, and possible 
strategies for cognitive enhancement (Geyer 2006; Jentsch, & Roth 1999).
Much of the mechanism by which NMDA antagonist induced PPI disruption occurs 
remains unknown. The NMDAR hypofunction theory suggests that NMDAR 
hypofunciton in the mPFC results in the cognitive and behavioral disruptions 
characteristic of schizophrenia (Olney, & Farber 1995; Adams, & Moghaddam 1998; 
Moghaddam et al 1997). It is thought that NMDAR antagonism may simulate NMDAR 
hypofunction, thus producing similar effects on behavioral and cognitive processes, 
possibly including PPI.
The medial prefrontal cortex (mPFC) has become an area of interest in the mechanism 
underlying the disruption of PPI by NMDAR antagonists in rats. The first study to 
evaluate this possibility examined the effect microinjections of a non-competitive NMDA 
antagonist (MK-801) to the mPFC (Bakshi, & Geyer 1998). It found trend level 
significance indicating a possible role for the mPFC in the mechanism. A subsequent
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study by Schwabe and Koch (2004) found that systemically administered MK-801 failed 
to disrupt PPI in rats with mPFC lesions, indicating that the mPFC may play a crucial 
role in mediating NMDA-antagonist induced PPI disruption. Another area of interest is 
the caudal pedunculopontine reticular nucleus (PnC), since it comprises the interface 
between the components of the sensorimotor system (Davis 1984), and also receives 
inhibitory input from the pedunculopontine tegmental nucleus (PPT), which includes the 
integrated PPI-modulating input of higher brain structures including the mPFC (Koch 
1999; Wu etal 1988).
In addition, the role of the diurnal cycle in sensorimotor gating and its modulation 
remains largely unknown. Many processes are modulated over the diurnal cycle, 
including: sleep, natural reward (ex. sex), and pharmacological reward (ex. amphetamine) 
(Yasenkov and Deboer, 2010; Moorman and Aston-Jones, 2010). PPI differences over 
the diurnal cycle have never been found, however Moorman and colleagues (2009) have 
recently demonstrated that orexin inputs alter mesolimbic responses to mPFC input 
differentially over the diurnal cycle. Since changes in mesolimbic dopamine levels are 
known to affect PPI (Swerdlow et al., 1990), it is possible that modulation of PPI differ 
over the diurnal cycle.
Thus, the aim of this work is to evaluate the role of NMDARs in the mPFC and the PnC 
in the mechanism underlying NMDA-antagonist induced PPI disruption, and possible 
subtypes involved. We also aim to explore modulation of PPI by NMDAR antagonists 
over the diurnal cycle. In order to achieve these objectives, we employed the use of both 
systemic and local injections of pharmacological agents to evaluate the mechanisms 




This research focuses on the glutamatergic mechanisms by which prepulse inhibition is 
modulated. This introduction will begin with an overview of prepulse inhibition and its 
modulation. The introduction will then turn to a discussion of current hypotheses 
regarding the deregulation of prepulse inhibition modulation thought to be associated 
with the cognitive symptoms of schizophrenia.
1. The startle response and its modulations are adaptive
The startle response can take many forms, but in mammals it can be characterized as a 
rapid twitch of facial and body muscles in response to a strong, sudden stimulus (Figure 
1.1). First described by Sechenov in 1863, the startle response is found across the animal 
kingdom (Currie, & Carlsen 1985; Baird et al 1993; Wicks et al 1996; Russell 1974; 
Prosser, & Hunter 1936; Pfeiffer 1962; Mongeluzi et al 1998; Zottoli et al 1999). This 
reflexive response to potentially aversive stimuli does not have to be learned. For 
example, strong acoustic stimuli begin to elicit the startle response in rats immediately 
after hearing develops around postnatal day 12 (Sheets et al 1988; Kungel et al 1996). In 
addition to acoustic stimuli, tactile and visual stimuli can also provoke startle responses 
(Li et al 2001; Yeomans et al 2002). It has even been found that in fish, olfactory stimuli 
can evoke the startle response (Pfeiffer 1962).
More specifically, the startle response consists of a contraction of facial and skeletal 
muscles, closure of the eyelids, cessation of normal behavior, and a rise in heart rate 
(Landis, & Hunt 1939; Koch 1999). This reaction may seem counter-productive to the 
survival of an organism as evinced by Graham’s statement that “It is difficult to see in 
what way the widespread flexor contractions [in startle] offer protection.” in her 1979 
work “The Orienting Reflex in Humans”. It is now thought that this set of reactions can 
be categorized as a defensive reflex, which serves to protect an individual from injury 
and to prepare for a flight/fight response (Koch 1999; Turpin 1986).
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Figure 1.1 The manifestation of the startle reflex, showing the rat immediately 
before (A) and 38ms after (B) the presentation of the startling acoustic 
stimulus (modified from: Horlington 1970).
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Despite the strength and reliability of the response, its amplitude can be modified by a 
variety of factors including: genetic traits (Bullock et al 1997; Acri et al 1995; Breier et al 
2010; Paylor, & Crawley 1997), diurnal rhythm (Chabot, & Taylor 1992; Davis, & 
Sollberger 1971), stress (Bakshi et al 2011), pharmacological manipulations, and ambient 
sensory surroundings such as illumination (Grillon et al 1997), background noise 
(Hoffman, & Fleshier 1963), preceding non-startling stimuli (Hoffman, & Ison 1980; 
Reijmers, & Peeters 1994). The focus of this work will be on the later form of 
modification, the inhibition of the acoustic startle response by preceding non-startling 
stimuli.
The first exploration of inhibitory reflex modification was done by Sechenov (Sechenov 
1965), as described in his 1863 work “Reflexes of the Brain”. This form of inhibitory 
reflex modification is now called “prepulse inhibition” (PP1); a term first coined by Ison 
and Hammond (1971). Prepulse inhibition can be described as an attenuation of the 
amplitude of the startle response to a strong, startling stimulus (pulse) following the 
presentation of a shortly preceding, non-startling stimulus (prepulse) (Ison, & Hammond 
1971). Some of the first evidence of prepulse inhibition in the auditory system was 
demonstrated by Peak (1939), and later by Hoffman (1965) who was the first to suggest 
prepulse inhibition may be a more general mechanism conducted through other 
modalities as well (Hoffman, & Searle 1965). Indeed, prepulse inhibition has been found 
to be multimodal, being elicited by tactile, visual, and auditory stimuli (Pinckney 1976; 
Buckland et al 1969; Graham 1980; Blumenthal, & Gescheider 1987; Braff et al 1992).
Prepulse inhibition (PPI) is a multimodal process, and is not a learning-related 
phenomenon. It can be executed upon an individual’s first exposure to a prepulse and 
pulse stimulus combination (Blumenthal et al 1996). So what adaptive advantage does 
prepulse inhibition afford an organism? It has been found that although the startle 
reaction is sometimes adaptive, in many situations it actually impairs normal functioning. 
For example, it has been demonstrated that trained lever pressing behavior in rats was 
disrupted following the presentation of startling stimuli, even after repeated exposure 
over a period of nine days (Hoffman 1971). It has also been found that the period during
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which the perception of a prepulse inhibits the startle reaction is the same time period 
during which pre-attentive processing of a stimulus occurs. During this time, initiation of 
the strong, reflexive behaviors comprising the startle response could disrupt stimulus 
identification (Graham 1979). One theory, termed Graham’s protection of processing 
theory (Li et al 2009; Fendt et al 2001), states that the presentation of a prepulse triggers 
a “transient detection reaction” which causes the attenuation of the startle response until 
the preceding stimulus has been properly processed (Graham 1975). This theory has been 
supported by many since its inception in 1975 by Graham (Cook, & Turpin 1997; 
Granholm et al 1999; Swerdlow 1996), and is supported by the fact that perception of the 
prepulse is critical to its ability to reduce the amplitude of a startle reaction (Blumenthal 
et al 1996; Blumenthal 1995; Mussat-Whitlow, & Blumenthal 1997; Perlstein et al 1989; 
Norris, & Blumenthal 1995; Norris, & Blumenthal 1996; Perlstein et al 1993; Filion et al 
1994).
2. Characteristics of prepulse inhibition
Prepulse inhibition is reliably and robustly elicited by prepulse and pulse stimulus 
combinations in rodents. PP1 magnitude remains fairly stable over time, even following 
repeated exposure to prepulses (Wu et al 1984; Blumenthal 1997). However, there are 
many factors that influence the magnitude of prepulse inhibition produced by a prepulse 
inhibition paradigm. Maximum startle inhibition (between 80-90%) (Fendt et al 2001) is 
produced with a prepulse length of 10-20ms (Reijmers, & Peeters 1994) using an 
interstimulus interval (IS1) of between 40 and 150ms in rats (Hoffman, & Ison 1980; Li 
et al 1998b; Li et al 1998a; Hoffman, & Searle 1965), and of about 120ms in humans 
(Graham, & Murray 1977). Increases in prepulse amplitude (PPA), approaching the 
threshold of the startle response, also augment prepulse inhibition (Li et al 1998a; 
Hoffman, & Eaton 1984; Hoffman, & Wible 1970; Hoffman, & Searle 1968). Thus, 
prepulse inhibition can be said to be strongly affected by prepulse amplitude and ISI, 
somewhat dependent on prepulse duration, and independent of the characteristics of the 
startling stimulus (Stitt et al 1976).
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The literature typically uses the term ‘pulse-alone trial' to denote a trial in which only the 
startling stimulus (pulse) is presented, while the term ‘prepulse-pulse trial' describes a 
trial in which a non-startling stimulus (prepulse) is presented shortly before the startling 
stimulus (pulse) producing prepulse inhibition. Much of the literature expresses prepulse 
inhibition as a percentage decrease of baseline startle amplitude following prepulse 
presentation as in the following formula:
% p rep u lse  inhibition
C prepulse  — pulse tr ia l' startle  response am plitude )
('pulse — alone tr ia l' startle  am plitude )
Although there has been some controversy over this quantification of PPI (Csomor et al 
2008), there have been multiple studies in support of this method (Ison et al 1997; 
Blumenthal 1997). For instance, it has been found that while certain experimental 
manipulations can produce amplification or reduction of the acoustic startle response 
(ASR) amplitude, prepulse inhibition when normalized to baseline startle amplitudes can 
remain constant (Koch, & Friauf 1995; Ison et al 1997; Swerdlow et al 1992). Likewise, 
in many instances where pharmacological manipulations have produced alterations in 
relative prepulse inhibition, ASR amplitude has remained unchanged (Fletcher et al 2001; 
Alsene et al 2010). It can thus be inferred that the respective pathways mediating the 
ASR and PPI are separate, and that PPI amplitudes are optimally expressed as 
percentages normalized to individual ASR amplitudes, rather than as scores of absolute 
ASR amplitude difference (Ison et al 1997).
j  * 100
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3. Circuitry mediating the startle response
Although the startle response can be elicited by tactile, vestibular, and acoustic stimuli, 
the acoustic modality is most commonly used in the lab for startle and prepulse inhibition 
experimentation. The acoustic startle response, and acoustic prepulse inhibition is used 
throughout this work; therefore all subsequent discussion will concern the acoustic startle 
response and acoustic prepulse inhibition.
The pathways mediating the ASR are located in the ponto-medullary brainstem, the 
primary startle pathway consisting of a very short trisynaptic pathway allowing for very 
fast transmission (For review see: Davis 1984; Koch, & Schnitzler 1997; Yeomans et al 
2002). For instance, the latency of the startle response, as measured from 
electromyography in neck or limb muscles is only about 10ms (Caeser et al 1989; 
Cassella et al 1986). The key structure in this short pathway is the caudal pontine 
reticular nucleus (PnC), which has been identified as the site of the startle mediating 
neurons, and forms the essential sensorimotor interface of the pathway (Koch, & 
Schnitzler 1997; Koch et al 1992; Lingenhohl, & Friauf 1994; Yeomans et al 1993). The 
giant cells of the PnC receive glutamatergic projections from the cochlear nuclei and 
cochlear root neurons (CN/CRN), and project to motor neurons of the cranial nerve and 
spinal cord to effect the muscular contractions that characterize the startle response 
(Scott et al 1999; Davis et al 1982; Lee et al 1996; Ebert, & Koch 1992; Yeomans, & 
Frankland 1995) (Figure 1.2).
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Acoustic input 1 Motor neurons i Motor output
Figure 1.2 Hypothetical circuit mediating the acoustic startle response. The pathway 
proposed to primarily and most rapidly mediate the ASR is demarcated by an orange 
border (modified from: Koch, & Schnitzler 1997).
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In addition, to this fast, primary startle pathway, there are other secondary pathways 
capable of mediating or modulating to the ASR through the transmission of auditory 
signals to the PnC. For example, the superior olivary nucleus (SOC), dorsal and ventral 
cochlear nuclei (DCN and VCN respectively), pedunculopontine tegmental nucleus 
(PPTg) and the ventral tegmental nucleus (VTN) have all been found to convey auditory 
input to the PnC (Randier, & Herbert 1991; Koch et al 1993; Koch, & Schnitzler 1997; 
Wagner 1996a; Wagner 1996b), and it has even been found through lesion studies that 
the superior olivary complex is required for full expression of the ASR (Wagner et al 
2000). Furthermore, excitatory postsynaptic potentials (EPSPs) recorded intracellularly 
from giant neurons of the PnC exhibit “exions or shoulders” at very reliable and specific 
latencies, suggesting that these cells indeed receive and integrate input from multiple 
afferent systems (Lingenhohl, & Friauf 1992; Lingenhohl, & Friauf 1994).
4. Circuitry mediating prepulse inhibition
Hoffman and Ison (1980) were the first to suggest that prepulse inhibition is mediated by 
a slower, inhibitory pathway that runs parallel to the fast, excitatory primary startle 
pathway. The dominant hypothesis states that this parallel feed-forward inhibitory 
pathway consists of three neural substrates in a serial arrangement: the inferior colliculus 
(IC), superior colliculus (SC), and the pedunculopontine tegmental nucleus (PPT) (for 
review see: Koch 1999; Fendt et al 2001) (Figure 1.3). As in the primary startle pathway, 
the parallel inhibitory PPI pathway receives acoustic input from the cochlear nuclei. 
Anatomical studies have shown that the cells of the cochlear nucleus directly innervate 
the cells of the 1C. Lesions of the inferior colliculus have been shown to almost 
completely eliminate prepulse inhibition of the acoustic startle response (Leitner et al 
1980; Leitner et al 1981; Li et al 1998a; Leitner, & Cohen 1985), and electrical 
stimulation of this area causes potent inhibition of the ASR (Li, & Yeomans 2000; Li et 
al 1998b). Thus, the IC has been identified as an integral part of the PPI pathway. The 
superior colliculus has also been identified as an important substrate in the PPI pathway 
due to the fact that it receives tactile and vestibular input in addition to acoustic input 
from the IC (Meredith et al 1992; García Del Cano et al 2006). Both electrical and
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pharmacological stimulation studies confirm that excitation of the SC produces 
significant prepulse inhibition (Li, & Yeomans 2000; Fendt 1999; Saitoh et al 1987). 
Finally the pedunculopontine tegmental nucleus became an area of interest as hodological 
studies revealed that the PPT receives multimodal sensory input from the SC (Redgrave 
et al 1987; Semba, & Fibiger 1992), and that the PPT sends cholinergic and GABAergic 
inhibitory afferents to the PnC (Bosch, & Schmid 2006; Bosch, & Schmid 2008; Koch et 
al 1993; Semba et al 1990; Yeomans et al 2010). The importance of the PPT in the 
pathway was further confirmed by work by Swerdlow and Geyer (Swerdlow, & Geyer 
1993) showing that lesions of the PPT severely disrupted PPI of the ASR, and by similar 
results following pharmacological inactivation of the PPT (Kodsi, & Swerdlow 1997).
This body of evidence strongly supports the aforementioned hypothetical PPI pathway, 
however it is important to note that none of the lesions or pharmacological manipulations 
of the substrates in the pathway completely abolished PPI. In fact, it has been suggested 
that the SC may not even be a necessary portion of the pathway mediating PPI of the 
ASR. Fiber-sparing lesions of the SC only reduced PPI of the ASR by about 45%, 
indicating that an alternate pathway must be involved in transmitting acoustic 
information to the PPT (Fendt et al 1994). In addition, a study of PPI latencies by Li and 
Yeomans was inconsistent with the placement of the IC before the SC in the proposed 
serial pathway. Li and Yeomans go on to suggest that there must be two parallel 
pathways mediating PPI, a more rapid pathway between the IC and the PPT for 
conveying auditory prepulses, and a slower pathway between the IC, SC, and PPT 
mediating multimodal prepulses (Li, & Yeomans 2000).
Despite that fact that prepulse inhibition is mediated by brainstem and midbrain 
structures, much recent work has demonstrated that PPI can be modulated by a number of 
higher-order cognitive processes (for review see: Li et al 2009). These modulations occur 
via a cortico-striatal-pallido-thalamic network that is thought to involve several neural 
substrates including the ventral hippocampus, amygdala, medial prefrontal cortex, 
thalamus, ventral striatum, ventral tegmental area, nucleus accumbens shell and core, 
locus coeruleus, ventral pallidum, and substantia nigra (Alsene, & Bakshi 2011; for
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review see: Swerdlow et al 2001; Koch 1999). These modulatory areas affect prepulse 
inhibition and the startle response through either direct or indirect projections to the PPT, 
which thus functions as a site of modulatory input integration. An example of a cognitive 
processes involved in PPI modulation is stress, the effects of which were investigated by 
Pijlman and colleagues (2003) by exposing rats to either physical stress (foot shocks), or 
emotional stress (watching a cage mate receive foot shocks) (Pijlman et al 2003).
Physical stress was found to disrupt prepulse inhibition, while emotional stress had no 
effect. Stress induced by a period of early maternal deprivation can also cause disruption 
of PPI, even at maturity in rats (Choy et al 2009). Additionally, attentional-modulation of 
PPI occurs in humans, and may also occur in rats. In a study done by Filion (1993) in 
humans, participants were instructed to pay attention to only one prepulse of a specific 
frequency. On trials that presented the ‘attended to’ prepulse, PPI was enhanced. 
Interestingly, in rats attention to prepulses is achieved through fear-conditioning to 
specific prepulses, theoretically making them behaviorally salient. Emotional 
manipulations that increase attention to prepulses in rats, as in humans, have been proven 
to cause potentiation of PPI (Du et al 2010).
To summarize, the process that generates PPI begins when an acoustic stimulus excites 
the CRN/CN. Excitatory auditory neurons then send projections to the ascending auditory 
pathway via the inferior colliculus. The neurons of the inferior colliculus then send input 
both directly, and indirectly via the SC, to the PPT (Yeomans et al 2006). The PPT 
integrates input from the auditory pathway as well as modulatory input from higher brain 
centers, and sends inhibitory input comprised of both cholinergic and GABAergic 
projections to the PnC (Bosch, & Schmid 2008; Bosch, & Schmid 2006; Koch et al 1993; 
Yeomans et al 2010). This inhibitory input finally causes attenuation of the ASR, or 
prepulse inhibition.
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Figure 1.3 Hypothetical circuits mediating acoustic prepulse inhibition of the startle 
response. The dashed grey arrows indicate acoustic sensory input. The thinner black 
arrows indicate the proposed parallel pathways mediating acoustic PPI of the startle 
response, while the bold black arrows denote the fast primary acoustic startle 
pathway. Pointed arrowheads show excitatory projections, and flat terminations 
show inhibitory projections.
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5. Prepulsc inhibition is an operational measure of sensory gating
The integrity of many of our higher cognitive processes, such as memory, attention, and 
general organization of thought, rely crucially on our ability to preattentively filter out 
irrelevant sensory information. Prepulse inhibition was first developed as a measure of 
automatic inhibition in normal subjects (Graham 1975; Peak 1939), however Braff (1978) 
was the first to use this measure to operationally identify sensorimotor gating deficits in 
psychiatric populations. The PP1 paradigm has since been used extensively to investigate 
sensorimotor gating deficits in disorders such as Tourette’s syndrome (Castellanos et al 
1996), bipolar disorder (Giakoumaki et al 2007), post-traumatic stress disorder (Grillon et 
al 1996), obsessive-compulsive disorder (Hoenig et al 2005), panic disorder (Ludewig et 
al 2002), autism (Perry et al 2007), Huntington’s disease (Swerdlow et al 1995), 
nocturnal enuresis (Omitz et al 1999), and most notably schizophrenia (Bolino et al 1994; 
Braff et al 1992; Braff et al 1999; Kumari et al 1999; Kumari et al 2000; Weike et al 
2000).
Schizophrenia affects about 0.4% of the population worldwide (Bhugra 2005), and exacts 
a huge economic toll through a number of costs including health care, lost productivity, 
monetary and emotional costs for family members, and social assistance or disability due 
to inability to maintain gainful employment (for review see: Percudani et al 2004). 
Symptoms of schizophrenia are generally categorized as positive symptoms (delusions, 
aggression, talkativeness, bizarre behavior, hallucinations, etc.), negative symptoms 
(affective flattening, poverty of speech, loss of motivation, social and emotional 
withdrawal, poor hygiene, etc.), or cognitive symptoms (disorganized thought, memory 
deficits, inattention, derailment) (Geyer 2006a; Walker, & Lewine 1988). A large 
component of the economic and social impact of schizophrenia originates in the difficulty 
that patients face in obtaining and retaining paid employment. Rates of truancy are much 
higher for people with schizophrenia than the general population, and their rates of 
employment in western nations hover around only 20%. Even those individuals that find 
work have significant problems with job tenure (Foster et al 1996; Cook, & Razzano 
2000; Knapp et al 2002; McCreadie et al 1992). It has been shown that work is an
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important goal for most individuals with mental illness, increasing self-esteem and 
overall ability to function through the fulfillment of many needs by providing economic 
independence and access to therapeutic treatments (Polak, & Warner 1996).
Despite the obvious benefits of employment, even with treatment many patients still 
cannot find and maintain work due to the persistence of the symptoms of schizophrenia. 
Although typical and atypical antipsychotics treat the positive symptoms of schizophrenia 
with differential success, the negative symptoms, and particularly the cognitive > 
symptoms are often poorly ameliorated by current therapies even after psychoses have 
abated (Keefe et al 2007; Geyer 2006b; Mintz 2007; Nuechterlein et al 2004). It has been 
shown that atypical, or second-generation, antipsychotics may be marginally more 
effective treatments of the cognitive symptoms of schizophrenia (Gallhofer et al 1999; 
Breier 1999). However, even when treated with atypical antipsychotics, meta-analysis 
done by Percudani and colleagues suggests that the benefits of atypical versus typical 
antipsychotics in terms of global functioning, employment and work productivity are 
modest at best (Percudani et al 2004). Due to the ineffectual treatment of cognitive 
symptoms by current pharmaceuticals, there has been tremendous interest in better 
understanding the pathophysiology of the cognitive symptoms of schizophrenia.
Initial interest in using PPI to experimentally explore and understand schizophrenia arose 
from clinical evidence that schizophrenic patients exhibit deficiencies in their ability to 
adequately filter out extraneous, disruptive sensory stimuli (Bleuler 1950; Kraepelin 
1919; McGhie, & Chapman 1961; Venables 1964). Although schizophrenic patients 
generally display PPI deficits, it has been difficult to correlate PPI deficits with common 
clinical indices of schizophrenia (for review see: Swerdlow et al 2008). However, PPI 
deficits have been correlated to cognitive function indicators such as measures of 
distractibility and attention (Karper et al 1996), and Rorschach inkblot tests of thought 
disturbance (Perry et al 1999; Perry, & Braff 1994). In schizophrenic patients, PPI levels 
have also been correlated to the Global Assessment of Functioning Scale, which 
evaluates overall function across psychological, social, and occupational domains 
(Swerdlow et al 2006). Deficits in PPI also extend beyond afflicted patients to clinically
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unaffected relatives (Sharma et al 2001; Cadenhead et al 2000), indicating that deficits in 
PPI may be genetically transmitted. The fact that PPI cannot be definitively linked to 
clinical state, but can be related to more global measures of function and cognition, has 
been suggested to indicate that PPI deficits are the result of genetic traits. These traits 
result in disrupted modulatory forebrain circuits that regulate sensory gating mechanisms, 
rather those networks that are associated with specific symptom states of schizophrenia 
(Swerdlow et al 2008). Thus, a better understanding of the cortico-striatal-pallido- 
thalamic circuits that modulate PPI could lead to: 1) a more complete understanding of 
how sensorimotor gating is modulated, and 2) how disruptions of this modulatory system 
could lead to cognitive and functional impairment. This knowledge is vital to 
development of new pharmaceuticals and novel targets for research.
To this end, many animal models have been created to investigate how PPI is modulated, 
and how PPI modulatory networks may be altered in schizophrenic patients. Social 
isolation in post-weanling pups causes disruptions of PPI, as well as other cognitive 
deficits, and has become a widely used model for exploring developmental theories o f  
schizophrenia (Jones et al 2011; Bakshi et al 1998; Weiss et al 1999; Rosa et al 2005; 
Krebs-Thomson et al 2001). The revelation that PPI deficits are genetically heritable has 
also fostered interest in creating genetic models of deficient PPI including: metabotropic 
glutamate receptor 1 (mGluRl) knock-out mice (Brody et al 2003); metabotropic 
glutamate receptor 5 (mGluR5) knock-out mice (Brody et al 2004b; Brody et al 2004a); 
N-methyl D-aspartate (NMDA) receptor subunit 1 (NR1) knock-down mice (Duncan et 
al 2006b; Duncan et al 2006a); AMPA receptor subtype GluR4 knock-out mice (Sagata 
et al 2010); and prostaglandin E2 EP2 receptor knock-out mice (Savonenko et al 2009).
The most pervasive method of studying the modulation of PPI however, is through the 
pharmacological disruption or potentiation o f PPI using a .variety of compounds such as 
dopamine agonists, serotonin agonists, muscarinic antagonists, GABA receptor agonists, 
and NMDAR antagonists (for review see: Barak 2009; Geyer et al 2001; Mohler et al 
2008; Yeomans et al 2010).
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In summary, the cognitive symptoms o f schizophrenia are not well resolved with current 
therapies, resulting in enormous social, emotional and economic costs. Greater 
knowledge of the mechanisms underlying the modulation of prepulse inhibition may shed 
light on the pathophysiology of the cognitive and functional deficits characteristic of 
schizophrenia. Through the,use of animal models of PPI disruption, and the development 
of novel drugs and research targets, improved treatment outcomes for schizophrenic 
patients may be realized.
6. Evidence for NMDA receptor mediated modulation of prepulse inhibition
The main focus of this research is on the mechanism of NMDA modulation of PPI in the 
mPFC. This section will provide an overview of the PCP/NMDA antagonist model of 
schizophrenia, NMDA antagonist-induced prepulse inhibition deficits (NAIPdef) in rats 
as a model to explore the role of glutamate in schizophrenia, and the possible role of the 
medial prefrontal cortex in mediating NAIPdef.
Phencyclidine and the NMDA hypofunction theory o f schizophrenia
The dopamine agonist model of schizophrenia has long been used as a tool in the 
discovery and evaluation of antipsychotic drugs (Carlsson, & Lindqvist 1963; Seeman 
1987). Currently antipsychotic treatments function via the blockade of D2 dopamine 
receptors (for review see: Coyle 2006; Snyder 1981; Seeman 2002). As previously 
discussed, although many patients are relieved of positive symptoms of schizophrenia by 
typical and second-generation antipsychotics, most patients remain substantially impaired 
by both negative and cognitive symptoms. There has therefore been significant interest in 
the exploration of other possible neurotransmitters involved in the pathophysiology of 
schizophrenia in order to gain an understanding of those components of schizophrenia 
which remain resistant to current therapies.
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Over- the past few decades, the potential role of the NMDA receptor system in 
schizophrenia has emerged as an area of promise in understanding the cognitive 
symptoms of schizophrenia. This area of research has it roots in research dating back to 
the 1950’s, which found that the dissociable anesthetic phencyclidine (PCP) induced a 
state of psychosis in humans reminiscent of schizophrenia (Luby et al 1959; Luby et al 
1962; Itil et al 1967; Domino, & Luby 1981; Garey 1979; Snyder 1988; Javitt 1987; 
Javitt, & Zukin 1991b; Snyder 1988; Javitt, & Zukin 1991a). The administration of PCP 
induces not only the positive, but also the negative and cognitive symptoms of 
schizophrenia (Javitt 1987; Javitt, & Zukin 1991b). Interestingly children are quite 
resistant to the effects of PCP, paralleling the developmental course of schizophrenia, 
which typically involves the development o f clinical symptoms in late adolescence or 
adulthood (Reich, & Silvay 1989). Although the model was of great interest, the 
mechanism of action remained unknown until the work of Lodge and colleagues in the 
1980’s produced evidence that PCP acts primarily through blockade of NMDA receptors 
(Deutsch et al 1989; Johnson 1987; Lodge et al 1987; Lodge, & Anis 1982). Since then it 
has been shown that other non-competitive NMDA antagonists, such as MK-801 and 
ketamine, produce similar psychomimetic effects (Mansbach, & Geyer 1991; Krystal et 
al 1994; Moghaddam 1994). Furthermore, the effects of PCP cannot be reversed by 
haloperidol, a typical antipsychotic, indicating that the mechanisms mediating the 
cognitive effects of PCP are independent of the dopaminergic system (Keith et al 1991; 
Geyer et al 1990). The use of NMDA antagonists has thus become a working model used 
to investigate the cognitive symptoms of schizophrenia.
The NMDA hypofimction theory proposes a general mechanism by which PCP and its 
congeners may exert their effects (for review see: Olney, & Farber 1995). Multiple 
studies have found that NMDA antagonists induce excessive release of glutamate (G lu); 
in cortical regions of the brain (Adams, & Moghaddam 1998; Moghaddam et al 1997). 
The theory suggests that the cognitive and behavioral disruptions generated by the 
hypofunction of NMDA receptors in the cortex are the result of this excessive release of 
Glu, and the subsequent overstimulation of postsynaptic neurons (Olney, & Farber 1995; 
Adams, & Moghaddam 1998; Moghaddam et al 1997).
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Support for the involvement of glutamate dysfunction in cognitive dysfunction is 
provided by genetic studies of schizophrenic patients, with particular emphasis on 
families with high susceptibility to the disorder. Multiple genes (for example, neuregulin, 
DISCI, COMT, dysbindin, and RGS4) have been identified as risk factors in the 
development of schizophrenia, and most of these genes play a role in the molecular 
biology of the synapse (Harrison, & Weinberger 2005). Glutamatergic synapses and 
processes seem to be disproportionately affected (Harrison, & Owen 2003; Moghaddam 
2003), especially NMDAR signaling, which is impacted upon by most of the 
aforementioned susceptibility genes. Furthermore, several postmortem and 
neuropathological studies have revealed altered expression of NMD A receptors in 
afflicted patients, affecting many o f the major glutamatergic signaling pathways 
associated with the pathophysiology of schizophrenia (For review see: Kristiansen et al 
2007)
Animal model o f  NMD A hypofunction -  NMDA antagonist-induced PPI disruption in rats
Animal models play an instrumental role in the development of pharmaceuticals to treat 
schizophrenia, and in the exploration of the underlying mechanisms of the modulation of 
sensorimotor gating. It has been found that non-competitive NMDA antagonists, such as 
PCP and MK-801, potently disrupt PPI in rats (Geyer et al 1990; Mansbach, & Geyer 
1989; Mansbach 1991). These drugs also mimick the PPI deficits observed in human 
patients (Bolino et al 1994; Braff et al 1992; Kumari et al 1999; Kumari et al 2000;
Weike et al 2000), and also induced PPI deficits under both acoustic and multimodal PPI 
paradigms (Mansbach, & Geyer 1989). NMDAR antagonism also reliably produces PPI 
deficits in mice (Curzon, & Decker 1998; Dulawa, & Geyer 1996; Furuya et al 1999) and 
non-human primates (Linn et al 1999; Javitt, & Lindsley 2001). Thus, despite anatomical 
and cognitive differences between species, the disruptive effects of NMDAR antagonists 
on sensorimotor gating appear to be fairly robust. It has thus been suggested that NMDA 
antagonism constitutes a relevant model for the study of schizophrenia in animals, with 
particular value in understanding symptoms currently resistant to pharmacotherapy 
(Coyle 2006; Neill et al 2010; Large 2007; Jentsch, & Roth 1999).
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Evidence for involvement o f the medial prefrontal cortex in the mediation ofNMDAR 
antagonist-induced prepulse inhibition deficit
Multiple substrates have been implicated in the mediation of NAIPdef. One of the first 
studies to identify neural substrates involved in NAIPdef was conducted by Bakshi and 
Geyer in 1998. The study identified multiple regions of interest, which had been 
previously shown to be involved in the modulation of PPI, and which had very high 
levels of PCP binding sites (Suzuki et al 1995). They found that of the regions tested 
(basolateral amygdala, BLA; dorsal hippocampus, DH; ventral hippocampus, VH; medial 
prefrontal cortex, mPFC; dorsomedial thalamus, DMT; and the nucleus accumbens, 
NAcc), PPI was only significantly disrupted by intracranial injections of MK-801 to the 
BLA and the DH. MK-801 injections to the mPFC only slightly disrupted PPI, and only 
at trend level significance leaving the role o f the mPFC somewhat inconclusive.
However, further evidence for the possible role o f the mPFC in NAIPdef was provided 
by evidence that fiber-sparing lesions of the mPFC eliminate the PPI disrupting effects of 
systemically administered MK-801, while having no effect on PPI following control 
injections (Figure 1.4). These lesions did not alter the PPI disruptive effects of 
apomorphine, a dopamine agonist. Thus, the mPFC may play an important role in the 
neuronal circuitry mediating NMDAR antagonist-induced prepulse inhibition deficits, 
and has become an important focus of research.
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(A) or apomorphine (2 mg/kg ) (B) in lesioned (n =11) and sham-lesioned (n =10) rats. 
Data shown are means of % PPI following vehicle treatment (white bars) and MK- 
801/apomorphine treatment (black bars), ± SEM (2-way ANOVA, *P < 0.05) (modified 
from: Schwabe, & Koch 2004).
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7. NMDA Receptors
NMD A receptors are crucial to many cortical functions including the transmission and 
processing of sensory information, learning and memory, synaptic plasticity, 
development, as well as neurological and psychiatric diseases (Collingridge, & Watkins 
1994). Part of the family of glutamatergic receptors, the ionotropic NMDA receptor is a 
tetramer composed subunits which can be divided into two families, NR1 and NR2 (Cull- 
Candy et al 2001). The NR1 subunit can exist as one of eight isoforms generated through 
alternative splicing, and is an essential component o f the tetramer without which no 
functional channel can be formed (Bradley et al 2006; Forrest et al 1994). The NR2 
family of subunits consists of four forms (NR2A-D), some of which may be substituted 
for two forms of NR3 subunits in certain parts of the nervous system, each of which 
imparts different pharmacological and electrophysiological properties and is expressed in 
a developmental^ and tissue-specific pattern (Lynch, .& Guttmann 2002): ■
The NMDA receptor is a voltage-gated cation channel characterized by high Ca 
permeability, and an Mg2+ plug in the pore region conferring a voltage dependent gating 
mechanism. These receptors are considered “molecular coincidence detectors” of neural 
firing because activation requires co-binding of glutamate and either glycine or D-serine 
at the glycine modulatory site, as well as removal of the Mg blockade via a-amino-3- 
hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor-mediated depolarization 
of the postsynaptic membrane (Tsien 2000). In addition, the influx of Ga ions that 
occurs upon NMDA receptor activation generates a cascade of intracellular events that 
modulate several processes underlying neuroplasticity such as long-term potentiation, 
dendritic patterning, spine modification and synaptogenesis, all o f which have been 
shown to be disrupted in schizophrenia and related animal models (Greer, & Greenberg 
2008; Wayman et al 2008). The open probability of this channel can also be modulated 
by a variety of allosteric binding sites for zinc, protons, and polyamines (Figure 1.5).
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The expression of NMD A receptors in the cerebral cortex is widespread, and has been 
estimated at about 80% of all cortical neurons (Conti et al 1994). Within cortex they tend 
to be expressed less densely in layer IV than in layers II-III and V-VI, and are mainly 
composed of NR1, NR2A and/ NR2B subtypes (Conti, & Minelli 1996; Conti 1997). 
They are also expressed preferentially by pyramidal cells, specifically in a multi-protein 
network called the post-synaptic density, located on dendritic spines (Conti et al 1999; 
Standaert et al 1999). However, it has also been found that NMDA receptors can function 
as auto- and heteroreceptors. Presynaptic NMDA receptor expression has been dectected 
at both symmetrical and asymmetrical synapses, suggesting that they also play a role in 
the facilitation of glutamate and GABA release (Conti et al 1994). NMDA receptors are 
also expressed by the giant neurons of the PnC. Although no histological studies have 
been conducted to show NMDAR expression in the PnC, electrophysiological studies 
have shown that both trigeminally and auditory-evoked EPSCs can be reduced by 
application o f the competitive NMDAR antagonist, AP-5 (Schmid et al 2003; Weber et al 
2002). Although NMDAR expression by the giant neurons of the PnC can be inferred 
from these findings, the NMDAR contribution to EPSCs in these neurons was found to 
be quite small (about 15%) (Schmid et al 2003).
The activity of NMDA receptors can also be modulated by the activity of another class of 
glutamatergic receptor, called metabotropic glutamate receptors (mGluRs) (for review 
see: Moghaddam 2004). Unlike ionotropic receptors, subtypes of this receptor are found 
in very discrete regional and cellular locations. Both mGluRs and mGluR2/3 are found 
primarily in corticolimbic areas, however mGluR2/3 is found in a number of presynaptic, 
postsynaptic, extrasynaptic and glial locations while mGluRs is found mainly in 
postsynaptic locations (Tamara et al 2001; Phillips et al 2000; Baude et al 1993; Bell et al 
2002; Lujan et al 1996; Romano et al 1995; Shigemoto et al 1993). Activation of mGluRs 
has been shown to potentiate NMDAR-evoked responses (Doherty et al 1997; Pisani et al 
1997; Awad et al 2000; Attucci et al 2001; Mannaioni et al 2001), while mGluR2/3 
activation has been shown to normalize glutamate release following NMDAR antagonism 
(Battaglia et al 1997; Moghaddam, & Adams 1998; Cartmell, & Schoepp 2000), making 
both o f these receptors targets for further investigation and drag discovery.
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Figure 1.5 A schematic illustration of NMDA receptor organization. Shown here are the 
superimposed tertiary structures of the NR1 and NR2 subunits and their N-terminal 
binding sites for glycine/D-serine and glycine as well as binding sites for endogenous 
and exogenous ligands (modified from: Kristiansen et al 2007).
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8. Diurnal modulation of PPI and the ASR
The first study to investigate the diurnal regulation of the ASR, done by Davis (1971), 
showed that the ASR shows a robust diurnal rhythm, with higher startle reactivity during 
the dark cycle. This result has been replicated by others, showing between 60% and 
100% higher startle responsiveness during the dark phase of the diurnal cycle (Davis and 
Sollberger, 1971; Chabot and Taylor, 1992).
The role of the diurnal cycle in the modulation of PPI has been investigated by only a 
couple of studies in the published literature, which concluded that PPI does not display a 
diurnal rhythm (Unger et al., 2006; Weiss 1999a). However, it has been found that certain 
neuropeptide hormones, called orexins, demonstrate a distinct diurnal rhythm (Moorman 
and Aston-Jones, 2010). Orexins also have been implicated in a number of processes 
such as reward seeking behavior and arousal (Cason et al., 2010; Sakurai, 2007). 
Systemically applied orexins have also been found to increase dopamine neuron activity 
in the VTA (Moorman and Aston-Jones, 2010). Increased dopaminergic activity in the 
VTA has been shown to increase dopamine release in the Nacc, which causes PPI deficits 
(Taber 1995; Swerdlow et al., 1990). It has been hypothesized that hypofunction of 
NMDARs in the mPFC may also result in increased dopaminergic neuron activity in the 
mesolimbic system. Since orexins seem to exert their effects almost exclusively during 
the dark cycle in rats, it is possible that NMDAR antagonists may have a diurnal 
modulatory effect on PPI.
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III. THESIS OBJECTIVES AND HYPOTHESES
1. Hypotheses
1. We hypothesize that NMDAR antagonism in the PnC is involved in mediating the PPI 
deficits induced by systemically administered non-competitive NMDAR antagonists, 
since the cells of the PnC express NMDARs and the primary startle pathway is 
glutamatergic (see sections: 3 [pg. 6-7]; 7 [pg. 21]).
2. We hypothesize that NMDAR antagonism in the mPFC is involved in the mechanism 
underlying NAIPdef, given previous lesion and microinjection data, as well as evidence 
for the involvement of the mPFC in the NMDAR hypofunction model of schizophrenia 
(see section: 6 [pg. 15-19])
3. Given that NMDAR activity, and the psychomimetic effects of systemically 
administered NMDAR antagonists can be modulated through mGluR2 /3 agonism, we also 
hypothesize that PPI deficits produced by NMDAR blockade can be ameliorated by the 
local activation of mGluR2 /3 receptors in the mPFC (see section: 7 [pg.21]).
4. Finally, we hypothesize that NMDAR antagonism has different effects on PPI and 
baseline startle over the diurnal cycle, given previous evidence that baseline startle 
reactivity increases during the night cycle, and that orexins differently modulate 
mesolimbic dopamine levels over the diurnal cycle to possibly affect PPI (see section: 8 
[pg- 23]).
2. Objectives
There are five main objectives to this work:
l.To confirm systemic effects of NMDAR antagonists on PPI and baseline startle 
amplitude with our behavioral paradigm
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2. To evaluate the role of specific subtypes of NMDARs in the PnC in the mediation of 
the systemic effects of NMDAR antagonists on PP1 and baseline startle amplitude
3. To evaluate the role of specific subtypes of NMDARs in the mPFC in the mediation of 
the systemic effects of NMDAR antagonists on PPI and baseline startle amplitude
4. To evaluate the effect of mGluR2/3 activation in the mPFC on the disruption of PPI and 
baseline startle amplitude by NMDAR antagonism
5. To explore the differences in the effects of NMDAR antagonists on PPI and baseline 
startle amplitude over the diurnal cycle
3. Approach
To explore this hypothesis, we will perform systemic and intracranial (intra-PnC and 
intra-mPFC) injections of various NMDAR antagonists and an mGluR agonist. After 
injections, we will test startle and prepulse inhibition to attain baseline startle values and 
prepulse inhibition scores. We will also utilize a controlled diurnal testing facility in 




Sprague Dawley rats obtained from Charles River® (Montreal, Quebec) were used for all 
experiments. Rats weighed approx. 250-300g at the time of surgery, and about 300-350g 
at the time of testing. Animals were group housed until surgery in clear plastic caging 
with a d  libitum  access to rat chow and water, and individually housed following surgery 
to prevent injury to the animals and damage to the implants. Animals were kept on a 
12:12 hour light-dark cycle with transitions at 7am and 7pm, in a temperature controlled 
room kept at 23°C.
2. Stereotaxic Surgery
Two to 5 days following arrival, rats underwent surgery to implant chronic indwelling 
cannulas (PlasticsOne, 28 gauge) targeted to one of the following areas: PnC (implanted 
at a 10° lateral angle), or mPFC. Animals were anesthetized via inhalation of 2% 
vaporized isoflorane (Forane) and 98% oxygen delivered to the nose cone attached to the 
stereotaxic apparatus (Stoelting). They also received injections of 0.05 mg/kg 
buprenorphine and 2.5 mg/kg ketoprofen for analgesia, and an injection of 5mL/kg 0.9% 
sterile saline to ensure proper hydration during recovery. Once anesthetized, the rat was 
fixed in a stereotaxic apparatus (Stoelting Co) using blunt ended earbars. The skull was 
then shaven and cleansed with soap, 70% ethanol, and finally an iodine paint (Betadine). 
A three centimeter mid-sagittal incision was then made to expose the skull, and the skin 
was then retracted to expose the sagittal and lamboid sutures. Cannula coordinates were 
measured using a stereotaxic apparatus and then the tips were lowered through holes in 
the skull drilled with an engraving drill (Dremel). The coordinates used were as follows: 
mPFC (DV: -3.50 mm, from skull surface; ML: ±  0.6 mm, from midline; RC: +3.00 mm, 
from bregma) and PnC (DV: -8.50 mm, from skull surface; ML: ± 2.50 mm, from 
midline; RC: - 2.00 mm, from lambda). The cannulas were anchored to the skull using 
four stainless steel bone screws and dental cement, and the wound was closed using silk
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suture. Stainless steel stylets (PlasticsOne) were inserted to keep the cannulas free of 
obstructions. After surgery, animals were allowed to heal for 4-7 days before handling. 
All procedures were approved by the University of Western Ontario Animal Use 
Committee, and complied with the ethical guidelines of the Canadian Council on Animal 
Care involving vertebrate animals in research.
3. Initial Handling and Exposure to Behavioral Paradigm
Handling was done daily for 1-2 min per rat to replace stylets, and habituate the subjects 
to handling. The rats were also tickled to increase their affinity for their handlers 
(Burgdorf & Panksepp 2001). Rats were handled for three consecutive days before any 
injection to ensure habituation to being handled by the experimenter. All subjects were 
also placed in the startle boxes on the day before testing for one exposure to the 
behavioural paradigm and confinement in the startle boxes. It has been shown that there 
is an initial PPI learning effect to some degree, and this pre-test exposure reduces the 
variability of the first session PPI test results.
4. Drugs
MK.-801 (Sigma), Ifenprodil (Sigma), and Ro 25-6981 (Sigma) were dissolved in 0.9% 
saline. LY 354740 (Tocris) was dissolved in 0.9% saline with 1 eq. NaOH. All drugs 
were maintained at -18°C following dissolution. MK-801 is a non-subtype specific, non­
competitive NMDA antagonist. It was administered systemically (0.01 mg/kg, 0.1 mg/kg,
1.0 mg/kg) and intracranially (5 mM, 50 mM). Both ifenprodil and Ro 25-6981 act as 
NR2B subtype specific, non-competitive NMDA antagonists. Ifenprodil was originally 
used as the NR2B antagonist in our experiments, however we also tested Ro 25-6981 due 
to suggestions that Ro 25-6981 is more specific, and has been shown in previous studies 
to display discriminative stimuli more similar to PCP than those displayed by ifenprodil 
(Chaperon et al 2003). Ifenprodil was administered both systemically (10 mg/kg) and 
intracranially (100 pM, ImM). Ro 25-6981 was also administered systemically (10 
mg/kg) and intracranially (500 pM). LY 354740 constitutes highly selective mGluR2/3
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agonist, and was administered intracranially (500 pM). All doses used are within the 
range of well-established doses in the literature (system ic M K -801 : Geyer et al 2001; 
Bortolato et al 2004; Schwabe, & Koch 2004; M K-801 m icro in fusion : Bakshi, & Geyer 
1998; Bakshi, & Geyer 1999; Zhang et al 2000; Figueroa-Guzman et al 2006; system ic  
ifenprod il: Ma et al 2011; Burgdorf et al 2011; ifenprodil microinfusion'. Ma et al 2007; 
Day et al 2011; Blair et al 2005; system ic  R o  25-6981: Chaperon et al 2003; Ro 25-6981  
m icro in fu sion : Hu et al 2009; Fantin et al 2007; L Y  354740 m icroinfusion: Jackson, & 
Moghaddam 2001; Mela et al 2006).
5. Systemic Injections
All systemic injections delivered 1 mL/kg of either saline or drug intraperitoneally using 
a 23 gauge syringe. Injections were pseudorandomized and saline balanced to ensure that 
the administration of multiple injections had no significant effect on PPL
6. Intracranial Drug Infusion
On all intracranial test days, animals were placed between the experimenter’s thighs in a 
blanket and massaged until calm. Then injectors were lowered into the cannulas. Injectors 
extend to a depth of 1 mm below the end of the cannula tip in the brain. Injectors were 
attached to Teflon tubing (Cole Parmer), which was attached to 5 pL Hamilton 
microsyringes mounted on a motorized pump (World Precision Instruments). Injections 
of 0.5 pL of saline or drug per side were done over a period of 4 minutes, and the 
injectors were left in place for an additional minute in order to ensure absorption of the 
bolus of drug. Following injections, stylets were sterilized and replaced, and subjects 
were returned to their home cages.
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7. Behavioral Testing
All behavioral testing was done in startle boxes (Med Associates). Each startle box 
consists of a sound insulated chamber containing a platform to which a Plexiglas rat 
chamber is affixed. The platform constitutes a piezoelectric transducer that measures the 
magnitude of an animal’s movements. Beside the Plexiglas rat chamber is a loudspeaker, 
which allows the delivery of acoustic stimuli during testing. The behavioral testing 
paradigm consisted of the following phases: the acclimation phase, block 1, and block 2. 
During the acclimation phase animals were exposed to the chambers and background 
noise for 3 minutes. The background noise consisted of 65dB white noise, and was 
played for the duration of the experiment. ‘Pulse-alone’ trials consist only of startle 
stimulus presentation, while ‘prepulse-pulse’ trials consist of the presentation of a weaker 
non-startling stimulus (prepulse) at a specific short interval, or interstimulus interval 
(ISI), before the startling stimulus. During next phase (block 1) 30 pulse-alone trials 
(105dB, 20ms duration) were delivered at 20s intervals. The final phase of testing 
consisted of the presentation of 70 trials consisting of the following 7 different acoustic 
stimuli at 30 second intervals: 10 pulse-alone trials (105 dB, 20ms duration); and 10 of 
each of six prepulse-pulse trial types with one of three different interstimulus intervals 
(12ms, 50ms, and 100ms) and one of two different prepulse sound pressure levels (75dB 
and 85dB).
8. Diurnal Behavioral Testing
Experiments examining the effects of pharmacological manipulations over the diurnal 
cycle were conducted in a controlled diurnal facility, allowing for control over ambient 
lighting to which the rats were exposed. Rats were transferred to the diurnal facility 2 
weeks prior to behavioral testing to allow the rats to adjust to their new light/dark cycle. 
The rats were entrained to a reversed 12 hour light/12 hour dark cycle. Illumination 
transitions occurred at 11 am and 11 pm. Light cycle testing was performed at 7am, and 
dark cycle testing was performed at 7pm.
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9. Data Analysis
The startle response to the 105dB tone was recorded for each pulse-alone and prepulse + 
pulse trial. PPI was calculated by using the following formula:
/  ( p r e p u l s e  — p u l s e  t r i a l  s t a r t l e  r e s p o n s e  a m p l i t u d e ) \
%  p r e p u l s e  i n h i b i t i o n  =  1 1 --------------;— ;-----------;--------------- ;---------- ;---------- ;------ — -----------1 * 100
\  ( p u l s e  — a l o n e  t r i a l  s t a r t l e  a m p l i t u d e ) j
The baseline startle amplitude was calculated by averaging the first 20 pulse-alone trials 
in block 1. PPI data are presented as means (±SEM). PPI results were analyzed by 
repeated measures two-way ANOVA (treatment and ISI) followed by p o s t hoc  Tukey’s 
HSD test. Baseline startle amplitude data were analyzed by one-way ANOVA followed 
by p o s t hoc  Tukey’s HSD test, or by paired t-test for two-group comparisons (P > 0.05). 
Any cannulated animals that displayed severely disrupted prepulse inhibition following 
saline injection (PPI of less than 40% across multiple ISIs) were excluded from analysis. 
Significant differences in means are shown with *P  < 0.05, and trend-level differences 
are shown with UP  < 0.1.
9. Histology
After completion of testing, animals were sacrificed using a CO2 chamber. Intracranial 
injection of 0.5 pL stock thionine solution was performed post-mortem, and the brains 
were removed and fixed in 10% formalin for two days. Brains were then immersed in 
10% formalin + 15% sucrose for cryoprotection during sectioning. The brains were 
frozen in crushed dry ice, and sectioned using a freezing microtome at thickness of 
50pm. Slices were mounted and stained with thionine, cover slipped, and examined for 
cannula placement. Cannula coordinate confirmation was performed using a rat brain 
atlas by Praxinos and Watson (Praxinos & Watson 2004). Within the PnC and mPFC, 
injection tips that reached or penetrated the limits of the area bilaterally were deemed 





In order to commence with our first objective, to identify areas involved in the 
mechanism of NMDA antagonist induced PPI disruption, we wanted to confirm the 
published drugs effects using our experimental protocols.
1.1 Effects of systemic NMDA antagonism by MK-801
MK-801 significantly disrupted PPI at both the 75 dB [ANOVA, F(3,24)=14.91, p<0.05] 
and 85 dB prepulse amplitudes [ANOVA, F{3,24)= 19.32, p<0.05]. P ost hoc  analyses 
revealed that both the 0.1 mg/kg and 1.0 mg/kg doses significantly disrupted PPI at all 
ISIs, while no significant disruption was observed at the 0.01 mg/kg dose. MK-801 also 
significantly increased baseline startle amplitude [ANOVA, F(3,24)=6.49, p<0.05]. P ost 
hoc  analyses showed that only the 0.1 mg/kg dose significantly increased baseline startle 
amplitude. It should also be noted that at the highest dose of MK-801, observations 
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Figure 2.1 Systemic MK-801 administration potently and significantly disrupts PPI and 
increases baseline startle amplitude at both 75 dB and 85 dB prepulse amplitudes. 
Systemic MK-801 also significantly increases baseline startle amplitude. Rats received 
intraperitoneal injections of 0.9% saline (control) and MK-801 (0.01 mg/kg, 0.1 mg/kg, 
1 mg/kg). Prepulse inhibition values at (A) 75dB and (B) 85dB prepulse levels shown 
are means ± SEM, n=7. (C) Baseline startle amplitudes shown are means ± SEM, n=7.
P  0.1: *P <  0.05.
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1.2 Effects of systemic NR2B-specific antagonism by ifenprodil and Ro 25-6981
Ifenprodil (10 mg/kg) was tested to evaluate the effect of systemic NR2B antagonism on 
PPL Ifenprodil had no significant effect on PPI at either the 75 dB [ANOVA,
F(l,10)=l .56, n.s. p>0.05] or 85 dB [ANOVA, F(l,10)=0.62, n.s. p>0.05] prepulse 
levels, or on baseline startle values (t-test, n=6, n.s. p>0.05) (Figure 2.2). The highly 
specific NR2B antagonist, Ro 25-6981, was also used to assess the contribution of the 
NR2B subunit to the mechanism of NMDA antagonist induced PPI disruption. Systemic 
injection of Ro-25-6981 (10 mg/kg) significantly disrupted PPI at both the 75 dB 
[ANOVA, F( 1,14)= 10.49, p<0.05] and 85 dB [ANOVA, F(1,14)=23.06, p<0.05] 
prepulse levels. P ost hoc  analyses indicated that these effects were significant at the 50 
ms and 100 ms ISIs for both prepulse levels. There was no significant effect of Ro 25- 
6981 on baseline startle amplitude (t-test, n=8, n.s. p>0.05) (Figure 2.3).
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Figure 2.2 Systemic ifenprodil administration has no effect on either or baseline startle 
amplitude. Rats received injections of 0.9% saline (control) and ifenprodil (10 mg/kg). 
Prepulse inhibition values at (A) 75 dB and (B) 85 dB prepulse levels shown are means 
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Figure 2.3 Systemic Ro 25-6981 administration significantly disrupts PPI at both 75 dB 
and 85 dB prepulse amplitudes, with no effect on baseline startle amplitude. Rats 
received intraperitoneal injections of 0.9% saline (control) and Ro 25-6981 (10 mg/kg). 
Prepulse inhibition values at (A) 75 dB and (B) 85 dB prepulse levels shown are means 
± SEM, n=8. (C) Baseline startle amplitudes shown are means ± SEM, n=8. V  < 0.1; *P  
<0.05.
38
1.3 Effects of systemic NMDA antagonism by MK-801 over the diurnal cycle
Systemic administration of MK-801 (0.1 mg/kg) significantly disrupted PPI during both 
the light and dark periods of the diurnal cycle at both the 75 dB [ANOVA, F (3,28)=7.27, 
p<0.05] and 85 dB [ANOVA, F (3,28)=9.29, p<0.05] prepulse levels. P o st hoc  analyses 
revealed that there was no significant difference in the effect of MK-801 on PPI over the 
diurnal cycle. Results also indicate a significant effect of treatment [ANOVA, 
F(3,28)=8.66, p<0.05] on baseline startle amplitude. P ost hoc analyses reveal that 
baseline startle amplitude following saline injection is significantly higher during the 
dark cycle, compared to during the light cycle. During the light cycle, MK-801 seems to 
have no significant effect on baseline startle reactivity, while during the dark cycle MK- 
801 seems to significantly reduce baseline startle reactivity. These baseline startle 
reactivity results are most likely erroneous and should not be considered given our 
previous results for systemic MK-801 administration (Figure 2.1) and those in the 
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Figure 2.4 Systemic MK-801 administration significantly disrupts PPI at both 75 dB and 85 
dB prepulse amplitudes, but this effect does not differ across the diurnal cycle. Rats received 
intraperitoneal injections of 0.9% saline (control) and MK-801 (0.1 mg/kg) during both the 
light cycle and dark cycle. Prepulse inhibition values at (A) 75 dB and (B) 85 dB prepulse 
levels across the diurnal cycle shown are means ± SEM, n=8. (C) Baseline startle amplitudes 
shown are means ± SEM, n=8. V  < 0.1; * P <  0.05.
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1.4 Effects of systemic NR2B-specific antagonism by Ro 25-6981 over the diurnal 
cycle
Ro 25-6981 (10 mg/kg) was administered systemically over the diurnal cycle to examine 
the possible effect of time of day on the effect of Ro 25-6981 on prepulse inhibition. PPI 
was significantly disrupted by Ro 25-6981 administration at both the 75 dB [ANOVA, 
F(3,28)=7.19, p<0.05] and 85 dB [ANOVA, F(3,28)=5.95, p<0.05] prepulse levels 
during both light and dark periods of the diurnal cycle. P o st analyses show that Ro 25- 
6981 significantly reduces PPI during both the light and dark cycles at all ISIs and 
prepulse levels, except the 12 ms ISI at the 75 dB prepulse level during the light cycle. 
However, there were no significant differences between the effects of Ro 25-6981 on PPI 
during the light and dark phases of the diurnal cycle respectively. Results also indicate a 
significant effect of Ro 25-6981 [ANOVA, F(3,28)=8.63, p<0.05] on baseline startle 
amplitude. P ost hoc  analyses reveal that baseline startle amplitude following saline 
injection is significantly higher during the dark cycle, compared to during the light cycle. 
During the light cycle, Ro 25-6981 seems to have no significant effect on baseline startle 
reactivity, while during the dark cycle Ro 25-6981 seems to significantly reduce baseline 
startle reactivity. These baseline startle reactivity results are most likely erroneous and 
should not be considered given our previous results for systemic Ro 25-6981 
administration (Figure 2.3) and those in the literature. This point will be further 
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Treatment
Figure 2.5 Systemic Ro 25-6981 administration significantly disrupts PPI at both the 75 
dB and 85 dB prepulse levels, but this effect does not significantly differ across the 
diurnal cycle. Rats received intraperitoneal injections of 0.9% saline (control) and Ro 
25-6981 (10 mg/kg). Prepulse inhibition values at (A) 75 dB and (B) 85 dB prepulse 
levels during both light and dark phases of the diurnal cycle shown are means ± SEM, 
n=8. (C) Baseline startle amplitudes shown are means ± SEM, n=8. V  < 0.1; *P < 0.05.
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2. Microinfusions
2.1 Local effects of NMDA antagonism by MK-801 in the PnC
In order to investigate the possible effects of NMDA antagonism on the primary startle 
pathway at the level of the PnC, microinjections of MK-801 (5 mM and 50 mM,
0.5pL/side) were performed in the PnC. ANOVA analyses indicate that there was no 
significant effect of MK-801 at the 75 dB [ANOVA, F(2,31)=2.56, n.s. p>0.05] or the 85 
dB [ANOVA, F (2,35)=0.87, n.s. p>0.05] prepulse levels, or on baseline startle values 
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Figure 2.6 Intracranial administration of MK-801 to the PnC had no significant effect 
on either PPI or baseline startle amplitude. Rats received bilateral intracranial injections 
of 0.9% saline (control, 0.5 pL/side) and MK-801 (5mM and 50mM, 0.5 pL/side) to the 
PnC. Prepulse inhibition values at (A) 75 dB (saline, n=13; 5 mM MK-801, n=13; 50 
mM MK-801, n=8) and (B) 85 dB (saline, n=15; 5 mM MK-801, n=15; 50 mM MK- 
801, n=8) prepulse levels shown are means ± SEM. (C) Baseline startle amplitudes 
shown are means ± SEM (saline, n=20; 5 mM MK-801, n=20; 50 mM MK-801, n=8). 
#P <  0.1; *P < 0.05.
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We also sought to examine the effect of local NR2B-specific antagonism on the PnC, 
thus intracranial injection of ifenprodil (1 mM, 0.5 pL/side) to the PnC was performed. 
Analyses demonstrated no main effect of drug on either PPI at the 75 dB prepulse 
amplitude [ANOVA, F(l,8)=6.62, n.s. p>0.05], or on baseline startle amplitude (t-test, 
n=5, n.s. p>0.05) (Figure 2.7).





















Figure 2.7 Intracranial administration of ifenprodil to the PnC has no significant effect 
on PPI at a 75 dB prepulse level, or on baseline startle amplitude. Rats received bilateral 
intracranial injections of 0.9% saline (control, 0.5 pL/side) and ifenprodil (1 mM, 0.5 
pL/side) to the PnC and tested at the 75 dB prepulse level. (A) Prepulse inhibition 
values shown are means ± SEM, n=5. (B) Baseline startle amplitudes shown are means 
± SEM, n=5. #P  < 0.1 ; *P < 0.05.
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2.3 Local effects of NMDA antagonism by MK-801 in the mPFC
Microinjections of MK-801 (5 mM and 50 mM, 0.5 pL/side) to the mPFC were 
performed to investigate its role in the emergent systemic disruption of PPI by non­
competitive NMDA antagonists.
Upon examination of the cannula placements, a distinct relationship between injection 
location within the mPFC and drug effect on PPI was observed (Figure 2.8). Injections of 
MK-801 located within approximately the dorsal third of the mPFC, and within the 
caudal most 0.5 mm of the rostro-caudal extent of the mPFC, had no effect on PPI at 
either the 75 db [ANOVA, F (2,36)=0.52, n.s. p>0.05] or 85 dB [ANOVA, F(2.24)=0.17, 
n.s. p>0.05] prepulse amplitudes, or on baseline startle amplitude [ANOVA, 
F(2,36)=61.71, n.s. p>0.05] (Figure 2.9). However, injections of MK-801 placed within 
the ventral two-thirds of the mPFC, over most of the rostro-caudal extent of the mPFC 
except the caudal-most area, significantly disrupted PPI at the 75 dB prepulse amplitude 
[ANOVA, F(2,32)=l 1.07, p<0.05]. P o st hoc  analyses indicate that both doses of MK-801 
(5 mM and 50 mM) significantly disrupted PPI. There was no significant effect of MK- 
801 in the same group at the 85 dB prepulse amplitude [ANOVA, F(2,12)=2.36, n.s. 




Figure 2.8 Illustration of coronal sections indicating the location of injector tips in 
the mPFC, and the local effect of MK-801 injection on PPI at each site. Each filled 
circle in one hemisphere represents injector tip placement in a different animal 
(animals received bilateral cannulation and injections). Each placement is colour 
coded according to the effect of local MK-801 antagonism on PPI in the originating 
animal: black — indicates an increase in PPI; unfilled circles -  indicates no 
conclusive effect on PPI; grey -  indicates a decrease in PPI. Coronal sections shown 
here are 0.24 mm apart, and the rostral-most section shown here is 3.72 mm anterior 
to bregma. Atlas illustrations adapted from the atlas of Paxinos and Watson 
{Paxinos 2005}.
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Figure 2.9 Intracranial administration of MK-801 to the dorsal-third and most caudal 
areas of the mPFC has no significant effect on PP1 or baseline startle amplitude. Rats 
received bilateral intracranial injections of 0.9% saline (control, 0.5 pL/side) and MK- 
801 (5 mM or 50 mM, 0.5 pL/side). Prepulse inhibition values at the (A) 75 dB (saline, 
n=15; 5 mM MK-801, n=15; 50 mM MK-801, n=9) and (B) 85 dB (saline, n=9; 5 mM 
MK-801, n=9; 50 mM MK-801, n=9) prepulse levels shown are means ± SEM. (C) 
Baseline startle amplitudes shown are means ± SEM (saline, n=15; 5 mM MK-801, 
n=15; 50 mM MK-801, n=9). *P <  0.1; *P<0.05.
49





100% i ^Sa line
■  5 mM MK-801

















■  5 mM MK-801
■  50 mM MK-801
1
Figure 2.10 Intracranial administration of MK-801 to the ventral two-thirds of the 
mPFC significantly disrupts PPI at the 75 dB prepulse level, with no effect on baseline 
startle amplitude. Rats received bilateral intracranial injections of 0.9% saline (control, 
0.5 pL/side) and MK-801 (5 mM or 50 mM, 0.5 pL/side). Prepulse inhibition values at 
the (A) 75 dB (saline, n=15; 5 mM MK-801, n=15; 50 mM MK-801, n=5) and (B) 85 
dB (saline, n=5; 5 mM MK-801, n=5; 50 mM MK-801, n=5) prepulse levels shown are 
means ± SEM. (C) Baseline startle amplitudes shown are means ± SEM (saline, n=15; 5 
mM MK-801, n=15; 50 mM MK-801, n=5). V <0.1; *P<0.05.
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2.4 Local effects of NR2B-specific antagonism by ifenprodil and Ro 25-6981 in the
mPFC
Microinfusion of non-competitive NMDA antagonists, ifenprodil (100 pM and 1 mM,
0.5pL/side) and Ro 25-6981 (500 pM, 0.5 pL/side), were also performed in the mPFC to 
evaluate the possible involvement of the NR2B subunit in the mediation of PPI disruption 
by NMDA antagonists. The same relationship between cannula placement and drug 
effect, noted in the group of animals treated with local administration of MK-801, was 
also noted within the group treated with ifenprodil. Thus, the group was similarly divided 
between hits in the ventral two-thirds of the volume of the mPFC, and hits in the dorsal 
third and most caudal portions of the mPFC.
Injections of ifenprodil located within approximately the dorsal third of the mPFC, and 
within the caudal most coronal section of the mPFC, had no effect on PPI at either the 75 
db [ANOVA, F(2,43)=0.39, n.s. p>0.05] or 85 dB [ANOVA, F(2,33)=0.82, n.s. p>0.05] 
prepulse amplitudes, or on baseline startle amplitude [ANOVA, F(2,43)=0.13, n.s. 
p>0.05] (Figure 2.11). However, injections of ifenprodil placed within the ventral two- 
thirds of the mPFC caused trend level disruption of PPI at the 75 dB prepulse amplitude 
[ANOVA, F(2,32)=3.10, p<0.1]. Student’s t-tests comparing vehicle and ifenprodil 
injections revealed that the high dose of ifenprodil (1 mM, 0.5 pL/side) significantly 
disrupted PPI at the 75 dB prepulse level (p < 0.05). There was no significant effect of 
ifenprodil in the same group at the 85 dB prepulse amplitude [ANOVA, F(2,12)=1.91, 
n.s. p>0.05], or on baseline startle amplitude [ANOVA, F(2,32)=1.38, n.s. p>0.05] 
(Figure 2.12).
Ro 25-6981 microinfusion to the mPFC had no significant effect on PPI at either the 75 
dB [ANOVA, F(l,12)=1.16, n.s. p>0.05] or the 85 dB prepulse levels [ANOVA, 
F(l,12)=0.59, n.s. p>0.05] or on baseline startle amplitude (t-test, n=7, n.s. p>0.05). All 
cannula placements in the group receiving microinfusions of Ro 25-6981 were within the 
same area found to result in significant PPI disruption by microinfusions of MK-801 in 
the mPFC (Figure 2.13).
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Figure 2.11 Intracranial administration of ifenprodil to the dorsal-third and most caudal 
area of the mPFC has no significant effect on PPI or baseline startle amplitude. Rats 
received bilateral intracranial injections of 0.9% saline (control, 0.5 pL/side) and 
ifenprodil (100 pM and 1 mM, 0.5 pL/side). (A) Prepulse inhibition at (A) 75 dB 
(saline, n=17; 100 pM ifenprodil, n=12; 1 mM ifenprodil, n=17) and (B) 85 dB (saline, 
n=12; 100 pM ifenprodil, n=12; 1 mM ifenprodil, n=T2) prepulse levels shown are 
means ± SEM. (C) Baseline startle amplitudes shown are means ± SEM (saline, n=17; 5 
mM MK.-801, n=12; 50 mM MK-801, n=17). #P <  0.1; *P<0.05.
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Figure 2.12 Intracranial administration o f ifenprodil to the ventral two-thirds of the 
mPFC causes trend level disruption of PPI at the 75 dB prepulse level, with no effect on 
baseline startle amplitude. Rats received bilateral intracranial injections of 0.9% saline 
(control, 0.5 pL/side) and ifenprodil (100 pM and 1 mM, 0.5 pL/side). (A) Prepulse 
inhibition at (A) 75 dB (saline, n=15; 100 pM ifenprodil, n=5; 1 mM ifenprodil, n=15) 
and (B) 85 dB (saline, n=5; 100 pM ifenprodil, n=5; 1 mM ifenprodil, n=5) prepulse 
levels shown are means ± SEM. (C) Baseline startle amplitudes shown are means ± 
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Figure 2.13 Intracranial administration of Ro 25-6981 to the ventral two-thirds of the 
mPFC had no significant effect on either PPI or baseline startle amplitude. Rats received 
bilateral intracranial injections of 0.9% saline (control, 0.5 pL/side) and Ro 25-6981 
(500 pM, 0.5 pL/side) to the mPFC. Prepulse inhibition values at (A) 75 dB and (B) 85 
dB prepulse levels shown are means ± SEM, n=7. (C) Baseline startle amplitudes shown 
are means ± SEM, n=7. *P < 0.1; *P  < 0.05.
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Ro 25-6981 (500 pM, 0.5 pL/side) was administered intracranially to the ventral two- 
thirds of the mPFC over the diurnal cycle to determine if its effects on PPI differ between 
light and dark periods. No significant effect of Ro 25-6981 on PPI was observed at either 
the 75 dB [ANOVA, F(3,24)=3.10, n.s. p>0.05] or 85 dB [ANOVA, F(3,24)=1.74, n.s. 
p>0.05] prepulse levels during either the light or dark phase of the diurnal cycle. There 
was a significant effect of treatment on baseline startle amplitude [ANOVA, 
F(3,24)=26.02, p<0.05]. P o st hoc  analyses indicate that baseline startle amplitudes were 
significantly higher during the dark cycle than during the light cycle, however Ro 25- 
6981 had no effect on baseline startle when compared to saline values during either the 
light or dark periods of the diurnal cycle (Figure 2.14).
2.5 Local effects of NR2B-specific antagonism by Ro 25-6981 in the ventral two
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Figure 2.14 Intracranial administration of Ro 25-6981 to the ventral two-thirds of the 
mPFC had no significant effect on either PPI or baseline startle amplitude. Rats received 
bilateral intracranial injections of 0.9% saline (control, 0.5 pL/side) and Ro 25-6981 
(500 pM, 0.5 pL/side) to the mPFC. Prepulse inhibition values at (A) 75 dB and (B) 85 
dB prepulse levels shown are means ± SEM, n=7. (C) Baseline startle amplitudes shown 
are means ± SEM, n=7. V  < 0.1; *P  < 0.05.
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2.5 Local effect of simultaneous 111GIUR2/3 activation and NMDA antagonism by 
MK-801 and LY 354740 in the ventral two-thirds of the mPFC
In order to investigate the effects of mGluR.2 /3 activation on the PPI disruption caused by 
local NMDA antagonism in the mPFC, vehicle (0.9 % saline), MK-801 (5 mM), and a 
combination of LY 354740 (500 pM) and MK-801 (5 mM) were injected into the ventral 
two-thirds of the mPFC (0.5 pL/side). There was no significant effect of drug in the 
mPFC at either the 75 dB [ANOVA, F(2,12)=1.80, n.s. p>0.05] or the 85 dB prepulse 
level [ANOVA, F(2,12)=0.57, n.s. p>0.05]. There was however, a significant effect of 
drug on baseline startle amplitude [ANOVA, F(2,12)=25.53, n.s. p>0.05]. P ost hoc  
analysis showed that the co-administration o f MK-801 and LY 354740 resulted in a 
significant increase in baseline startle amplitude compared to both vehicle and MK-801 
injections. This result is likely erroneous, and will be explained in the discussion section. 
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Figure 2.15 Intracranial co-administration of MK-801 and LY 354740 to the ventral 
two-thirds of the mPFC had no significant effect on PPI and increased baseline startle 
amplitude. Rats received bilateral intracranial injections of vehicle (0.9% saline), MK- 
801 (5 mM), and a combination of MK-801 (5 mM) and LY 354740 (500 pM) to the 
mPFC (0.5 pL/side). Prepulse inhibition values at (A) 75 dB and (B) 85 dB prepulse 
levels shown are means ± SEM, n=5. (C) Baseline startle amplitudes shown are means ±  




M icro in fusions - D rug  C oncentra tion
Microinfusion studies encounter criticism due to the fact that A) one cannot predict the 
actual drug concentration following injection due to a number of unknown parameters 
such as blood perfusion, diffusion volume, and tissue metabolism, and that B) these 
studies often employ drug concentrations between 1 0  and 1 0 0 0  times greater than those 
found to be effective in electrophysiological studies. That being said, it has been found 
that diffusion volume of drug is mostly confined to a radius of about 1 mm from the 
injection site, and that drug levels beyond this radius, even up to an hour after injection, 
remained below behaviorally relevant concentrations (Singer, & Montgomery 1973).
However, determining appropriate injection concentrations remains an issue. Many 
studies only find behavioral effects at concentrations several orders of magnitude higher 
than electrophysiologically relevant concentrations (Sircar et al 1987; Maione et al 1998; 
Kim et al 2010; Jackson, & Moghaddam 2001; Schoepp et al 1997; Figueroa-Guzman et 
al 2006). For instance, while Ro 25-6981 was found to block NMDA receptors expressed 
in xenopus oocytes with an IC50 value of 9 pM (Fischer et al 1997), Ro 25-6981 has been 
applied via microdialysis at a concentration of 145 pM and via microinfusion at a 
concentration of 2.6 mM (Hu et al 2009; Fantin et al 2007). In attempting to select a Ro 
25-6981 concentration safely within the published range, we chose a 500 pM 
concentration of Ro 25-6981 for microinjection to the mPFC. Contrary to our 
expectations, this concentration of Ro 25-6981 had no effect on PPI when locally 
administered to the mPFC while both ifenprodil and MK-801 produced PPI disruption. It 
is likely that our results indicating no effect of locally administered Ro 25-6981 is due to 
the application of an insufficiently high concentration.
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Elimination o f animals and pseudorandomization
Many animals were eliminated from the data set presented in this work due to post­
operative prepulse inhibition deficits following saline injection, in particular following 
cannulation targeting the mPFC. In addition, animals receiving mPFC targeted 
cannulation were also divided into two groups based on the observation that animals 
receiving MK-801 microinfusion to the mPFC showed no effect of drug on PPI when 
cannula placements were located in approximately the dorsal third, and the most caudal 
0.5 mm coronal area of the mPFC. Conversely, injections within the ventral two-thirds of 
the mPFC resulted in significant disruption of PPI (Figure 2.8). Based on these results, 
only injections located within the ventral two-thirds of the mPFC were included in 
analyses and considered effective hits for all tested drug effects in the mPFC. These 
exclusion criteria resulted in the elimination of many animals, and sometimes resulted in 
skewed pseudorandomization of treatment administration order. These imbalances in 
pseudorandomization could produce erroneous instances of significant effects of drug or 
lack thereof. It should also be noted that due to time and scheduling constraints, animals 
receiving systemic NMDA administration over the diurnal cycle were not 
pseudorandomized for treatment order.
2. Effects of systemic NMDA antagonism on PPI and baseline startle amplitude
We show that the systemic administration of the non-subtype specific, non-competitive 
NMDA antagonist MK-801 has the effect of disrupting PPI and increasing baseline 
startle amplitude. Also evident in the work presented here is that systemic administration 
of the NR2B-specifc, non-competitive NMDA antagonist Ro 25-6981 also results in 
disruption of PPI, but unlike MK-801 has no significant effect on baseline startle 
amplitudes. These results agree with previously published reports of the effects of MK- 
801 and Ro 25-6981 on PPI and baseline startle amplitude (Mansbach, & Geyer 1989; 
Chaperon et al 2003; Bortolato et al 2004). Thus, we can confirm that NMDA receptor 
inhibition significantly disrupts PPI, and that NR2B receptors play a role in this effect.
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In contrast, systemic administration of the NR2B-specific, non-competitive NMDA 
antagonist ifenprodil was shown here to have no significant effect on either PPI or 
baseline startle amplitude. To the best of our knowledge the effect of systemic 
administration on PPI has not been previously reported in the literature, however we did 
expect to see a disruption of PPI by ifenprodil since Ro 25-6981, also an NR2B-specific 
antagonist, resulted in significant PPI disruption. It is possible that in order to observe 
PPI disruption by ifenprodil, a higher dose is necessary. However, it has been shown that 
systemic administration of ifenprodil ( 1 0  mg/kg), the same dose used in our experiment, 
significantly disrupts corticolimbic processes such as positive emotional learning, and 
spatial memory acquisition and retrieval (Ma et al 2011; Burgdorf et al 2011). Thus, it 
seems unlikely that the dose used was insufficient.
It has been demonstrated that although non-competitive NMDA antagonism generally 
produces psychomimetic effects characteristic of schizophrenia, non-competitive NMDA 
antagonists exert modulatory effects on NMDA receptors through a number of different 
mechanisms and with varying levels of psychomimetic efficacy. For instance, systemic 
ketamine administration produces a discriminative stimulus that rats may be trained to 
differentiate from saline treatment. This paradigm can be used to evaluate the similarity 
of the discriminative stimuli produced by other NMDA antagonists to that of ketamine, in 
order to indirectly evaluate their psychomimetic generalizability to ketamine. In a 
discriminative study of NR2B involvement in the generation of psychomimetic effects by 
ketamine, it has been demonstrated that ketamine, MK-801, PCP, and Ro 25-6981 all 
resulted in complete stimulus generalization (>80%), while ifenprodil caused only partial 
generalization (33%) (De Vry, & Jentzsch 2003). It is not known precisely why these two 
NR2B antagonists have different efficacy in producing schizomimetic symptoms, 
particularly because they have been proven to bind to the same site on the NR2B subunit 
(Lynch et al 2001). However, it has been suggested that the mechanisms by which they 
alter the activity of the NMDA receptor differ, as evidence shows that while ifenprodil 
IC5 0 values decrease as spermidine concentration increases, the effect of Ro 25-6981 is 
unaffected by polyamine modulation (Lynch et al 2001). Ro 25-6981 also has a much 
higher binding affinity for NR2B-containing receptors than does ifenprodil (Mutel et al
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1998). These findings seem to indicate that although ifenprodil has some psychomimetic 
action, it is not as effective as MK-801, PCP, ketamine, and Ro 25-6981. It may be that to 
demonstrate effects on PPI these effects must reach a certain threshold, and that although 
the dose used was sufficient to disrupt other cognitive processes, a higher dose ( > 1 0  
mg/kg) may be required to disrupt PPI given its lesser ability to produce psychomimetic 
symptoms. Taken together, this evidence may provide an explanation of why the effects 
of systemically administered Ro 25-6981 and ifenprodil have divergent effects on PPI.
3. Intra-PnC effect of NMDA antagonism on PPI and baseline startle amplitude
Our results indicate that neither MK-801 nor ifenprodil micro injections targeting the PnC 
have any effect on PPI and baseline startle amplitude. To the best of our knowledge, there 
have been no published investigations into the effects of intra-PnC non-competitive 
NMDA antagonism. However, studies have indicated that local administration of a 
competitive NMDA antagonist, AP-5, to the PnC causes significant reductions in 
baseline startle amplitude (Miserendino, & Davis 1993; Krase et al 1993). The receptor 
subtypes mediating the effect of AP-5 likely don’t include NR2B, since expression is 
shifted almost exclusively to cortical regions between post-natal day 1 2  and adulthood 
(Monyer et al 1994). Based on these investigations, we expected to find a decrease in 
baseline startle following MK-801 administration, and no significant ifenprodil-induced 
decreases in baseline startle amplitude. There is evidence that MK-801 and AP-5 exhibit 
significantly different mechanisms of action. MK-801 is an open-channel blocker, 
binding to an in-channel PCP site and thereby blocking the channel pore. MK-801 
blockade development has also been shown to be use-dependent, meaning that NMDAR 
activation in the presence of its ligands is required to block the channel, as well as to 
release the blockade of the channel (for review see: (Kemp et al 1987)). AP-5 is a 
competitive NMDA-antagonist, which acts in a competitive manner for the glutamate 
binding site (Roller, & Urwyler 2010). The significantly different modes of NMDA 
receptor blockade, may account for the discrepancies found between our results and the 
published literature.
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4. Intra-mPFC effect of NMDA antagonism on PPI and baseline startle amplitude
MK-801 microinfusion to the mPFC has been previously shown to cause only trend-level 
inhibition of PPI (Bakshi, & Geyer 1998). A study done by Schwabe and colleagues 
(2004) however, found that bilateral lesions of the mPFC completely eliminated the PPI- 
disrupting effects of systemically applied MK-801, indicating that the mPFC is a crucial 
actor in the mechanism mediating the psychomimetic effects of systemic NMDA 
antagonism. To our knowledge, ours is the first study to conclusively demonstrate 
significant disruption of PPI following local NMDA receptor antagonism in the mPFC.
We found significant disruption of PPI following local injection of both doses of MK-801 
at the 75db prepulse level, as well as a significant disruption of PPI by ifenprodil at the 
75 dB prepulse level. In contrast, Ro 25-6981 microinfusions to the mPFC had no effect 
on PPI. We had originally expected all of these compounds to significantly disrupt PPI 
since NMDA receptors, including the NR2B subtype, are highly expressed in cortex 
(Monyer et al 1994; Standaert et al 1999). As previously mentioned in our discussion of 
the methodological issues with our work, and given the highly potent psychomimetic 
activity of Ro 25-6981 (Chaperon et al 2003; De Vry, & Jentzsch 2003), it is likely that 
the dose of Ro 25-6981 used here (500 pM) was insufficient. However, microinfusions of 
the NR2B antagonist, ifenprodil, to the mPFC did cause disruption of PPI despite its 
lesser psychomimetic properties in comparison to MK-801 as previously discussed. Thus, 
our work does confirm the involvement o f the NR2B subunit in the mechanism 
underlying the NMDA-antagonist induced disruption of PPI.
Our results also showed a relationship between injection location within the mPFC and 
the effect of NMDA antagonism. Only injections to the ventral two-thirds of the mPFC 
were effective in disrupting PPI. Injections to the dorsal third, and the most caudal 0.5 
mm of the mPFC had no effect on PPI. These results indicate a possible methodological 
issue with microinfusions, in that it is possible that the diffusion of drug is biased towards 
upward spread around the cannula. This would necessitate more ventral injection
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locations in order to ensure that the drug spreads to the appropriate target. However, our 
results could also be an indication that, despite the dominant view of the mPFC as a fairly 
undifferentiated structure (Kolb 1984), a functional heterogeneity exists within the 
mPFC. This division between the dorsal and ventral injection sites with respect to the 
effect of NMDA antagonism within the prelimbic cortex of rats may explain the 
inconclusive effect of local NMDA antagonism found by previous studies (Bakshi, & 
Geyer 1998).
We also performed local co-injections of MK-801 and an mGluR.2/3 agonist, LY 354740. 
Unfortunately, it seems that the small size of the group, and the unbalanced 
pseudorandomization of animals following eliminations of inadmissible animals, resulted 
in erroneous results. Since MK-801 administration alone had no significant effect on PPI 
in this group of animals, and given that we have demonstrated that there is an effect of 
local NMDA antagonism within the mPFC when group sizes are larger and proper 
pseudorandomization is achieved, we cannot make any conclusions about the effect of 
mGluR.2/3 activation on the PPI disrupting effect of local NMDA antagonism.
5. Effects of NMDA antagonism over the diurnal cycle
We found that the effects of systemically administered MK-801 and Ro 25-6981 on PPI 
did not differ over the course of the diurnal cycle. Since no effect of Ro 25-6981 on PPI 
was observed, likely due to an insufficient dose as previously discussed, we cannot 
comment definitively on the effect of this drug over the diurnal cycle. However, our 
systemic results match the published literature, in that differences in PPI and its 
modulation by pharmacological agents over the diurnal cycle have never been found 
(Unger et al., 2006; Weiss et ah, 1999).
We also found that baseline startle amplitude was significantly higher during the night 
cycle than during the dark cycle in the animals receiving local Ro 25-6981 injections to 
the mPFC. These results match the published literature, indicating that baseline startle 
reactivity is increased during the dark cycle (Davis, & Sollberger 1971; Grillon et al
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1997). Unfortunately, the data for baseline startle reactivity cannot be conclusively 
interpreted. Due to the fact that MK.-801 administration in this group had no effect on 
baseline startle during the light cycle in contrast to our previous findings and the 
published literature, we concluded that the data for baseline startle amplitude were 
skewed by the lack of pseudorandomization of treatment order in this group.
Overall, we can conclude that our results matched the published literature in that PP1 is 
not modulated differently over the diurnal cycle, and that baseline startle reactivity 
increases during the dark cycle.
6. Potential mechanism underlying NMDA-antagonist induced PPI deficits
Our results confirm that the mPFC plays a role in mediating the PPI-disrupting effects of 
systemically administered NMDA antagonists, and that the NR2B subtype is involved in 
this mediation. It has been suggested that NMDA antagonists exert their effects mainly 
through action on GABAergic cells. Indeed, it has been found that NMDA antagonists 
have a ten-fold greater effect on GABAergic cells compared to pyramidal cells (Grunze 
et al 1996). Evidence also indicates that in awake rats, systemic MK-801 administration 
results in decreased activity of putative intemeurons in the mPFC and a delayed increase 
in the activity of pyramidal neurons (Homayoun, & Moghaddam 2007). Thus, it is 
possible that systemic NMDA antagonists exert proportionally greater effects on 
GABAergic cells than on pyramidal cells leading to disinhibition of pyramidal cells in 
the mPFC. This disinhibition would cause increased glutamate realease, and indeed it has 
been found that ketamine application via microdialysis to the PFC results in increased 
glutamate release (Adams, & Moghaddam 1998; Moghaddam et al 1997). This increase 
in glutamate release is thought to be mediated by non-NMDA receptor activation on post- 
synaptic pyramidal neurons, since previous studies indicate that the effects of NMDA 
antagonists in the PFC can be blocked by blockade of AMPA/Kainate receptors by 
CNQX (Jedema, & Moghaddam 1994). It has been suggested that the overstimulation of 
postsynaptic neurons, and subsequent disinhibition of major excitatory pathways could 
lead to the psychomimetic effects of NMDA antagonists (Olney, & Farber 1995). The
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mPFC is known to send excitatory projections to the VTA (Geisler et al., 2007). It has 
also been demonstrated that increases in activity of the mPFC leads to increased burst 
firing of dopaminergic neurons in the VTA (Murase et al., 1993; Gariano and Groves, 
1988). These increases in VTA dopaminergic neuron activity cause increases in accumbal 
dopamine release, which has been shown to disrupt PPI (Taber et al., 1995; Swerdlow et 
al., 1990). Thus, it is likely that increased activity of the mesolimbic dopamine system 





Here, we investigated the underlying mechanisms of NMDA-antagonist induced PPI 
deficits in rats. The results are summarized in point form as follows:
1. Systemic MK-801 and Ro 25-6981 disrupted PPI while only MK-801 increased 
baseline startle reactivity. Ifenprodil had no effect on either PPI or baseline startle 
amplitude.
2. Effects of NMDA antagonists do not differ over the diurnal cycle
3. MK-801 and ifenprodil have no intra-PnC effect on PPI or baseline startle
4. Intra-mPFC MK-801 and ifenprodil disrupt PPI, with no effect on baseline startle 
reactivity, only when injected in to the ventral two-thirds of the mPFC
2. Implications for the NMDA-antagonist induced PPI disruption model
Our results indicate that the PnC plays no role in the mediation of the systemic effects of 
NMDA antagonists on PPI and baseline startle reactivity, despite the probable expression 
of NMDA receptors in the PnC.
This work is also the first to definitively demonstrate local NMDA antagonism in the 
mPFC causes PPI disruption. This finding supports earlier findings that the mPFC is a 
necessary part of the network mediating the systemic effects of NMDA antagonists. Our 
results also suggest that the mPFC (prelimbic cortex) may not be an undifferentiated 
structure, given that only NMDA antagonist injections to the more ventral regions of the 
mPFC affected PPI disruption. Thus, our findings make important contributions to the 
field by furthering our understanding of the mechanisms by which PPI is modulated, and 
by confirming that NMDA hypofunction in the mPFC may be partially responsible for 
the PPI deficits characteristic of schizophrenia.
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